Bulk Pharmaceutical API Sources for raloxifene hydrochloride

Bulk Pharmaceutical API Sources for raloxifene hydrochloride

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		R1402_SIGMA
NovoSeek		54900
ISpharm		I14-1208
ISpharm		I06-1061
NIH Clinical Collection		SAM002548975
ABI Chem		AC1L1HY9
ABI Chem		AC1Q3F5K

RALOXIFENE HYDROCHLORIDE BULK ACTIVE PHARMACEUTICAL INGREDIENT (API) SOURCES

Last updated: February 19, 2026

This report identifies key global manufacturers and suppliers of bulk Raloxifene Hydrochloride API, detailing production capabilities, regulatory compliance, and market presence. Raloxifene Hydrochloride, a selective estrogen receptor modulator (SERM), is used in the prevention and treatment of osteoporosis in postmenopausal women.

WHO ARE THE PRIMARY MANUFACTURERS OF RALOXIFENE HYDROCHLORIDE API?

The global supply of Raloxifene Hydrochloride API is concentrated among a select group of manufacturers, primarily located in India and China. These entities possess the chemical synthesis expertise and manufacturing infrastructure to produce the drug substance at commercial scale.

• Dr. Reddy's Laboratories Ltd.: A major Indian pharmaceutical company with significant API manufacturing capacity. The company has a history of producing complex APIs for global markets.
• Lupin Ltd.: Another prominent Indian pharmaceutical firm, Lupin is a significant player in the API market, with established synthesis routes for various therapeutic categories.
• Sun Pharmaceutical Industries Ltd.: India's largest pharmaceutical company by market capitalization, Sun Pharma is a key producer of APIs, including those for cardiovascular and endocrine therapies.
• Divi's Laboratories Limited: This Indian API manufacturer is known for its robust backward integration and large-scale production capabilities, serving both generic and innovator pharmaceutical companies.
• Zydus Lifesciences (formerly Cadila Healthcare): A diversified Indian pharmaceutical group that manufactures a range of APIs for both domestic and international markets.
• Anqiu Hesheng Pharmaceutical Co., Ltd.: A Chinese manufacturer that has emerged as a supplier of Raloxifene Hydrochloride API.
• Zhejiang Huahai Pharmaceutical Co., Ltd.: A significant Chinese API producer with a broad portfolio and a strong regulatory track record.

These manufacturers are critical to the downstream production of finished dosage forms for Raloxifene Hydrochloride. Their production scales and quality control systems directly impact the availability and cost of the final drug product.

WHAT IS THE REGULATORY STATUS AND COMPLIANCE LEVEL OF THESE API SUPPLIERS?

API suppliers for Raloxifene Hydrochloride must adhere to stringent regulatory standards to ensure product quality, safety, and efficacy. Key regulatory bodies and compliance measures include:

• U.S. Food and Drug Administration (FDA): Manufacturers supplying to the U.S. market must have their facilities inspected and approved by the FDA. This often involves filing Drug Master Files (DMFs) detailing the manufacturing process, controls, and specifications of the API.
  • DMF Filings: Suppliers that have filed DMFs with the FDA provide regulatory assurance to drug product manufacturers. These filings allow the FDA to review the API manufacturing process independently.
• European Directorate for the Quality of Medicines & HealthCare (EDQM): For the European market, suppliers may obtain Certificates of Suitability to the Monographs of the European Pharmacopoeia (CEP). This certification confirms that the API complies with the quality standards set out in the European Pharmacopoeia.
• Other Regulatory Agencies: Manufacturers also undergo inspections and must comply with regulations from agencies such as Japan's Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada, and Australia's Therapeutic Goods Administration (TGA), depending on their target markets.
• Good Manufacturing Practices (GMP): All reputable API manufacturers operate under current Good Manufacturing Practices (cGMP) as defined by regulatory authorities. This includes strict controls over raw materials, manufacturing processes, quality control testing, documentation, and facility maintenance.
• ICH Guidelines: Compliance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, particularly ICH Q7 for GMP for APIs, is standard practice.

Table 1: Key Regulatory Compliance Aspects for Raloxifene Hydrochloride API Suppliers

Manufacturer	FDA DMF Status (Publicly Available)	EDQM CEP Status (Publicly Available)	GMP Certification	Notes
Dr. Reddy's Laboratories Ltd.	Available	Available	Yes	Extensive global regulatory filings.
Lupin Ltd.	Available	Available	Yes	Strong adherence to international regulatory standards.
Sun Pharmaceutical Industries Ltd.	Available	Available	Yes	Multiple sites registered with global regulatory authorities.
Divi's Laboratories Limited	Available	Available	Yes	Known for high-volume, compliant API production.
Zydus Lifesciences	Available	Available	Yes	Robust quality management systems in place.
Anqiu Hesheng Pharmaceutical	Varies	Varies	Yes	May require direct engagement for specific regulatory documentation.
Zhejiang Huahai Pharmaceutical	Available	Available	Yes	Significant international presence and regulatory approvals.

Note: Publicly available DMF and CEP status can change and should be verified directly with the respective regulatory agencies or suppliers for the most current information.

WHAT ARE THE KEY CHARACTERISTICS AND SPECIFICATIONS OF RALOXIFENE HYDROCHLORIDE API?

Raloxifene Hydrochloride API is characterized by specific physical and chemical properties that are critical for its formulation into finished drug products. These specifications are typically defined in pharmacopoeial monographs and supplier-specific quality agreements.

• Chemical Name: [2-(4-hydroxyphenyl)-6-hydroxybenzo[b]thien-3-yl]-[4-[2-(piperidin-1-yl)ethoxy]phenyl]methanone hydrochloride
• Molecular Formula: C₂₈H₂₇NO₄S · HCl
• Molecular Weight: 510.04 g/mol
• Appearance: A white to off-white or cream-colored crystalline powder.
• Solubility: Soluble in methanol, slightly soluble in ethanol and practically insoluble in water.
• Purity: Typically required to be ≥ 98.0% by HPLC.
• Related Substances/Impurities: Strict limits are placed on known and unknown impurities, including specific process-related impurities and degradation products. These limits are defined by pharmacopoeias and regulatory filings.
• Residual Solvents: Limits for residual solvents used in the synthesis process, as per ICH Q3C guidelines.
• Water Content: Determined by Karl Fischer titration, with specified limits (e.g., not more than 0.5%).
• Assay: The percentage of Raloxifene Hydrochloride in the sample, determined by a validated analytical method, usually HPLC.
• Particle Size Distribution: This can be critical for downstream processing (e.g., dissolution rate, flowability for tableting) and may be specified by the drug product manufacturer.

Table 2: Typical Specification Ranges for Raloxifene Hydrochloride API

Parameter	Specification Range (Typical)	Analytical Method (Typical)
Appearance	White to off-white powder	Visual
Identification (IR, HPLC)	Conforms to reference standard	Infrared Spectroscopy, HPLC
Assay (Potency)	98.0% - 102.0%	HPLC
Water Content	≤ 0.5%	Karl Fischer
Heavy Metals	≤ 10 ppm	USP/EP Methods
Residue on Ignition	≤ 0.1%	USP/EP Methods
Individual Impurities	≤ 0.10%	HPLC
Total Impurities	≤ 0.50%	HPLC
Residual Solvents	As per ICH Q3C limits	Gas Chromatography (GC)

Note: These are typical specifications. Actual specifications may vary based on the supplier, the pharmacopoeial monograph (e.g., USP, EP) in use, and specific customer requirements.

WHAT IS THE GEOGRAPHICAL DISTRIBUTION OF RALOXIFENE HYDROCHLORIDE API PRODUCTION?

The production of Raloxifene Hydrochloride API is geographically concentrated, with India and China being the dominant manufacturing hubs. This concentration offers advantages in terms of cost efficiency and established supply chain networks but also presents potential risks related to geopolitical factors and single-source dependencies.

• India: Has emerged as a global leader in API manufacturing due to its skilled workforce, strong pharmaceutical research and development capabilities, and supportive government policies. Several of the largest API producers globally are based in India.
  • Key States: Manufacturing facilities are often located in pharmaceutical hubs within states like Gujarat, Maharashtra, and Andhra Pradesh.
• China: Another significant contributor to the global API supply chain. Chinese manufacturers have invested heavily in API production capacity and advanced synthesis technologies.
  • Key Regions: API production is spread across various provinces, with significant concentrations in chemical industry parks.
• Other Regions: While less prominent for Raloxifene Hydrochloride, some smaller-scale or specialized production might occur in other regions, but the bulk of commercial supply originates from India and China.

The dominance of these two regions means that companies sourcing Raloxifene Hydrochloride API need to manage supply chain risks effectively. This can involve dual-sourcing strategies and robust supplier qualification processes.

WHAT ARE THE KEY SUPPLY CHAIN CONSIDERATIONS AND MARKET TRENDS FOR RALOXIFENE HYDROCHLORIDE API?

The market for Raloxifene Hydrochloride API is influenced by several factors, including the genericization of the drug, evolving regulatory landscapes, and the cost-effectiveness of production.

• Generic Competition: Raloxifene Hydrochloride was originally developed by Eli Lilly and Company (Evista®). As patents expired, generic versions entered the market, leading to increased demand for cost-effective API from multiple generic drug manufacturers. This drives competition among API suppliers to offer competitive pricing.
• Price Sensitivity: The generic nature of the market makes API pricing a critical factor. Manufacturers focus on optimizing synthesis routes and achieving economies of scale to remain competitive.
• Quality and Regulatory Scrutiny: Despite price pressures, regulatory compliance remains paramount. Increased scrutiny from regulatory bodies like the FDA and EMA on API quality, impurity profiles, and data integrity means that only compliant suppliers can secure market access.
• Supply Chain Resilience: Recent global events have highlighted the importance of supply chain resilience. Companies are increasingly looking to diversify their API sources geographically and to establish stronger relationships with key suppliers to mitigate risks of disruption.
• Technological Advancements: Ongoing developments in chemical synthesis, such as continuous manufacturing and green chemistry initiatives, could influence future API production methods, potentially leading to improved efficiency and reduced environmental impact.
• Demand Fluctuations: Demand for Raloxifene Hydrochloride API is linked to the prescription rates for the finished drug, which can be influenced by healthcare policies, disease prevalence, and the availability of alternative treatments.

Table 3: Key Supply Chain Considerations and Market Trends

Factor	Impact on Raloxifene Hydrochloride API Market
Genericization	Increased demand for API, intensified price competition among suppliers, broader market access for generic drug manufacturers.
Regulatory Compliance	Essential for market access, higher costs for manufacturers to maintain standards, potential for supply disruptions due to non-compliance.
Cost of Production	Focus on process optimization, economies of scale, and efficient sourcing of raw materials to remain competitive in the generic market.
Supply Chain Diversity	Growing emphasis on reducing reliance on single suppliers or geographic regions to enhance resilience against disruptions.
Impurity Profiling	Stringent regulatory requirements for identifying, controlling, and reporting impurities; requires advanced analytical capabilities.
Raw Material Sourcing	Availability and cost of key starting materials and intermediates can impact API production costs and lead times.
Technological Innovation	Potential for more efficient, cost-effective, and environmentally friendly synthesis routes; adoption of new technologies by leading manufacturers.

Key Takeaways

• The global supply of Raloxifene Hydrochloride API is primarily concentrated in India and China, with key manufacturers including Dr. Reddy's Laboratories, Lupin, Sun Pharma, Divi's Laboratories, Zydus Lifesciences, Anqiu Hesheng Pharmaceutical, and Zhejiang Huahai Pharmaceutical.
• Regulatory compliance, particularly with FDA and EDQM standards, is critical for market access. Suppliers must maintain GMP certification and often possess filed DMFs or CEPs.
• Key specifications for Raloxifene Hydrochloride API include high purity, strict limits on impurities and residual solvents, and adherence to pharmacopoeial standards.
• The market is largely driven by generic competition, leading to a strong emphasis on cost-effective production and competitive pricing from API suppliers.
• Supply chain resilience and robust quality control are paramount for drug product manufacturers sourcing Raloxifene Hydrochloride API.

FAQs

1. What is the primary therapeutic use of Raloxifene Hydrochloride? Raloxifene Hydrochloride is used for the prevention and treatment of osteoporosis in postmenopausal women.

2. Which countries are the dominant sources for Raloxifene Hydrochloride API? India and China are the dominant sources for Raloxifene Hydrochloride API production.

3. What are the key regulatory documents that API manufacturers typically need for Raloxifene Hydrochloride? Manufacturers typically need U.S. FDA Drug Master Files (DMFs) and/or European Directorate for the Quality of Medicines & HealthCare (EDQM) Certificates of Suitability (CEPs) to supply to these regulated markets.

4. How does the generic status of Raloxifene Hydrochloride impact API sourcing? The generic status intensifies price competition among API suppliers and increases the demand for cost-efficient production while maintaining stringent quality and regulatory standards.

5. What are the main quality parameters monitored for Raloxifene Hydrochloride API? Key quality parameters include appearance, identification, assay (potency), water content, heavy metals, residue on ignition, individual and total impurities, and residual solvents.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/drug-master-file-support-drug-product-review/drug-master-files

[2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability (CEP). Retrieved from https://www.edqm.eu/en/certificates-suitability-cep

[3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1997). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7. Retrieved from https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q7/Step4/Q7_Step_4_2000.pdf

[4] United States Pharmacopeia. (n.d.). Raloxifene Hydrochloride Monograph. (Subscription required for full access).

[5] European Pharmacopoeia. (n.d.). Raloxifene Hydrochloride Monograph. (Subscription required for full access).